Back
Open Access

Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3

Session: Young Investigator Award (YIA) Basic Science
Topic: Cardio-Oncology
Speaker: Doctor V. Quagliariello (Naples, IT)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
0 follower

3 more presentations in this session

Engineering genetic resilience for cardiometabolic HFpEF: the crucial role of redox homeostasis

Speaker: Doctor M. Pepin (Stanford, US)

Access
Abstract
Like
Thumbnail

Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy

Speaker: Mr F. Deiman (Groningen, NL)

Access
Abstract
Like
Thumbnail

A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy

Speaker: Miss K. Kohlat (German Heart Center Of Charite Berlin, DE)

Access
Abstract
Like
Thumbnail

Access the full session

Young Investigator Award (YIA) Basic Science

Speakers: Doctor V. Quagliariello, Doctor M. Pepin, Mr F. Deiman, Miss K. Kohlat
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources